ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2598

Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study

Christelle Princivil1, thierry Lequerre2, Didier Alcaix3 and Olivier Vittecoq4, 1Jacques Monod hospital center, 76290 Montivilliers, France, montivilliers, France, 2Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France, 3Rheumatology Department, Jacques Monod Hospital Center, 76290 Montivilliers, France, montivilliers, France, 4INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Assessment, Spondylarthritis and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatments and diagnosis of SpA is a public health problem. The efficacy of anti-TNF alpha treatment is different from one patient to an other. In 2013, the ASAS society modified the Berlin algorithm, allowing us to define different subgroups of patients. The aim of the study was to compare the anti-TNF alpha response in the eight phenotypes of patients defined by the ASAS modified Berlin algorithm.

Methods: This French retrospective study was performed using the active file of patients suffering of SpA, in the University Hospital of Rouen, since 2005 from 2015, and using an anti-TNF alpha treatment. Patients diagnosed as having SpA by the rhumatologists of the hospital were included. The ASDAS-CRP and BASDAI score were calculated for all the patients at the initiation of the treatment (M0) and one year later (M12). The primary endpoint was the improvment of the ASDAS-CRP score after one year of treatment.

Results: 331 patients were included and distributed according to the modified algorithm (figure 1).69(%) had radiographic sacroiliitis , 117 (35%) had positive MRI, and 149(45%) had positive HLA-B27. All the groups were similar for their average age at the start of the treatment. The duration of the disease was lower in the group 7 (7.2±3 years), higher in group 1 (14.7±11.3 years). The male and female distribution was similar only in the first three groups, the proportion of female were higher in groups 4 to 8 ( Table 1). The ASDAS-CRP and BASDAI scores were significantly improved in all groups excepts in the group6. Nevertheless, the magnitude of this improvment is greater in the groups 1, 2 and 3.In group 1: ASDAS-CRP at M0 was 3.41 and 2.04 at M12 (p<0,0001).In group 2 ASDAS-CRP M0 was 3.12 and 2.15 at M12.(p< 0,0001).In group 3 ASDAS-CRP M0 was 3,1 and 1.9 at M12 (p<0,0001) ( figure 2).

Conclusion: This study demonstrates the heteregeneous response in patients with SpA, distributed according to the modified algorithm of Berlin, after one year of treatment with anti-TNF alpha.This algorithm wich is basically a diagnostic tool, can help us to define the populations of patients for wich anti TNF alpha treatment would be more relevant.


















Disclosure: C. Princivil, None; T. Lequerre, None; D. Alcaix, None; O. Vittecoq, None.

To cite this abstract in AMA style:

Princivil C, Lequerre T, Alcaix D, Vittecoq O. Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-anti-tumor-necrosis-factor-tnf-alpha-therapy-in-patients-with-spondylarthritis-in-the-university-center-of-rouen-in-france-divived-to-the-berlin-algorithm-modified-by-the-assessement-s/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-anti-tumor-necrosis-factor-tnf-alpha-therapy-in-patients-with-spondylarthritis-in-the-university-center-of-rouen-in-france-divived-to-the-berlin-algorithm-modified-by-the-assessement-s/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology